In The News

Real-World Outcomes of Sipuleucel-T Treatment in PROCEED, a Prospective Registry of Men With Metastatic Castration-Resistant Prostate Cancer

Celestia S. Higano, MD1; Andrew J. Armstrong, MD, ScM2,3; A. Oliver Sartor, MD4; Nicholas J. Vogelzang, MD5; Philip W. Kantoff, MD6; David G. McLeod, MD, JD7; Christopher M. Pieczonka, MD8; David F. Penson, MD, MPH9,10; Neal D. Shore, MD11; Jeffrey Vacirca, MD12; Raoul S. Concepcion, MD13; Ronald F. Tutrone, MD14; Luke T. Nordquist, MD15; David [...]

By | September 17th, 2019|

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate with Prednisone Tolerability (REAAcT)

Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Peig, Tracy McGowan Click here to read more

By | August 19th, 2019|

Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States

Jeremy B. Shelton, Thomas A. Paivanas, Phil Buffington, Stephen R. Ruyle, Edward S. Cohen, Richard Natale II, Bryan Mehlhaff, Ronald Suh, Timothy J. Bradford, Alec S. Koo, Lorna Kwan, Neal Shore Click here to read more  

By | August 19th, 2019|

Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States

Jeremy B. Shelton, Phil Buffington, Richard Augspurger, Franklin Gaylis, Todd Cohen, Bryan Mehlhaff, Ronald Suh, Timothy J. Bradford, Lorna Kwan, Alec S. Koo,  Neal Shore to read more. click here

By | August 19th, 2019|

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Christian Kappeler, Ph.D., Amir Snapir, M.D., Ph.D., Toni Sarapohja, M.Sc., and Matthew R. Smith, M.D., Ph.D. for the ARAMIS Investigators* Background- Darolutamide is [...]

By | February 18th, 2019|

Managing Nonmetastatic Castration-resistant Prostate Cancer

Joaquin Mateo, Karim Fizazi, Silke Gillessen, Axel Heidenreich, Raquel Perez-Lopez, Wim J.G. Oyen, Neal Shore, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Scott A. Tomlins, Johann S. de Bono. Correspondence information about the author Johann S. de Bono Associate Editor: Giacomo Novara Context Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and [...]

By | February 12th, 2019|

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

Neal D.Shore, MD, SílviaGuerrero, PhD, Rosa MaSanahuja, MS, GemmaGambús, MD, PhD, AntonioParente, Ph Purpose This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. click here to read more...

By | February 12th, 2019|

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

Neal D. Shore, MD1; Sílvia Guerrero, PhD2; Rosa Ma Sanahuja, MS2;Gemma Gambús, MD, PhD2; and Antonio Parente, PhD2 Purpose: This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. Click here to read more

By | February 1st, 2019|

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), which is designed to specifically bind PSMA‐positive cells, internalize, and then release its cytotoxic payload into the [...]

By | January 28th, 2019|